Latest news with #SingaporePaincareHoldings
Yahoo
24-05-2025
- Business
- Yahoo
Can Mixed Fundamentals Have A Negative Impact on Singapore Paincare Holdings Limited (Catalist:FRQ) Current Share Price Momentum?
Most readers would already be aware that Singapore Paincare Holdings' (Catalist:FRQ) stock increased significantly by 47% over the past three months. However, we decided to pay attention to the company's fundamentals which don't appear to give a clear sign about the company's financial health. Particularly, we will be paying attention to Singapore Paincare Holdings' ROE today. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. We've discovered 3 warning signs about Singapore Paincare Holdings. View them for free. The formula for ROE is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Singapore Paincare Holdings is: 8.5% = S$2.0m ÷ S$24m (Based on the trailing twelve months to December 2024). The 'return' is the yearly profit. That means that for every SGD1 worth of shareholders' equity, the company generated SGD0.08 in profit. Check out our latest analysis for Singapore Paincare Holdings We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. On the face of it, Singapore Paincare Holdings' ROE is not much to talk about. However, its ROE is similar to the industry average of 10%, so we won't completely dismiss the company. But Singapore Paincare Holdings saw a five year net income decline of 14% over the past five years. Bear in mind, the company does have a slightly low ROE. So that's what might be causing earnings growth to shrink. So, as a next step, we compared Singapore Paincare Holdings' performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 4.6% over the last few years. The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. Is Singapore Paincare Holdings fairly valued compared to other companies? These 3 valuation measures might help you decide. While the company did payout a portion of its dividend in the past, it currently doesn't pay a regular dividend. This implies that potentially all of its profits are being reinvested in the business. In total, we're a bit ambivalent about Singapore Paincare Holdings' performance. While the company does have a high rate of profit retention, its low rate of return is probably hampering its earnings growth. Wrapping up, we would proceed with caution with this company and one way of doing that would be to look at the risk profile of the business. To know the 3 risks we have identified for Singapore Paincare Holdings visit our risks dashboard for free. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
23-05-2025
- Business
- Yahoo
Can Mixed Fundamentals Have A Negative Impact on Singapore Paincare Holdings Limited (Catalist:FRQ) Current Share Price Momentum?
Most readers would already be aware that Singapore Paincare Holdings' (Catalist:FRQ) stock increased significantly by 47% over the past three months. However, we decided to pay attention to the company's fundamentals which don't appear to give a clear sign about the company's financial health. Particularly, we will be paying attention to Singapore Paincare Holdings' ROE today. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. We've discovered 3 warning signs about Singapore Paincare Holdings. View them for free. The formula for ROE is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Singapore Paincare Holdings is: 8.5% = S$2.0m ÷ S$24m (Based on the trailing twelve months to December 2024). The 'return' is the yearly profit. That means that for every SGD1 worth of shareholders' equity, the company generated SGD0.08 in profit. Check out our latest analysis for Singapore Paincare Holdings We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. On the face of it, Singapore Paincare Holdings' ROE is not much to talk about. However, its ROE is similar to the industry average of 10%, so we won't completely dismiss the company. But Singapore Paincare Holdings saw a five year net income decline of 14% over the past five years. Bear in mind, the company does have a slightly low ROE. So that's what might be causing earnings growth to shrink. So, as a next step, we compared Singapore Paincare Holdings' performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 4.6% over the last few years. The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. Is Singapore Paincare Holdings fairly valued compared to other companies? These 3 valuation measures might help you decide. While the company did payout a portion of its dividend in the past, it currently doesn't pay a regular dividend. This implies that potentially all of its profits are being reinvested in the business. In total, we're a bit ambivalent about Singapore Paincare Holdings' performance. While the company does have a high rate of profit retention, its low rate of return is probably hampering its earnings growth. Wrapping up, we would proceed with caution with this company and one way of doing that would be to look at the risk profile of the business. To know the 3 risks we have identified for Singapore Paincare Holdings visit our risks dashboard for free. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
